PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1574950
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1574950
Peptide Antibiotics Market size was valued at USD 4,804.09 Million in 2023, expanding at a CAGR of 11.20% from 2024 to 2032.
The peptide antibiotics market involves the development and sale of antibiotics made from small proteins called peptides. These antibiotics are effective against bacteria and can help treat infections, especially those resistant to traditional antibiotics. The market is growing due to increasing bacterial resistance and the need for new treatments. Researchers are exploring different peptides to find new drugs that are safe and effective. This area of medicine is important for public health as it offers hope in the fight against stubborn infections. Overall, peptide antibiotics represent a promising solution in the battle against antibiotic resistance.
Peptide Antibiotics Market- Market Dynamics
Increasing antibiotic resistance drives demand for peptide antibiotics innovation.
The rise of antibiotic resistance is a big problem that is increasing the demand for peptide antibiotics. According to the Centers for Disease Control and Prevention (CDC), there are more than 2.8 million antibiotic-resistant infections in the U.S. every year, leading to over 35,000 deaths. This is a serious issue and shows we need new treatments because many common antibiotics no longer work well.
Peptide antibiotics could be a good solution. They work differently than regular antibiotics, and researchers are looking into their special features to fight antibiotic resistance. These unique properties make peptide antibiotics effective against resistant bacteria, giving us hope for better ways to control infections.
Peptide Antibiotics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.20% over the forecast period (2024-2032)
Based on product type segmentation, Ribosomal Synthesized Peptide Antibiotics was predicted to show maximum market share in the year 2023
Based on Disease segmentation, Skin Infection was the leading type in 2023
Based on Route of Administration segmentation, Injectables was the leading type in 2023
based on Region, North America was the leading revenue generator in 2023
The Global Peptide Antibiotics Market is segmented based on Product Type, Disease, Route of Administration, and Region.
The market is divided into two categories based on Product Type: Ribosomal Synthesized Peptide Antibiotics, and Non-Ribosomal Synthesized Peptide Antibiotics. Ribosomal Synthesized Peptide Antibiotics are the most prominent segment. This is mainly because they work well against various infections, especially those caused by Gram-positive bacteria. They are often easier to take by mouth, which makes patients more likely to follow their treatment. With the rise of antibiotic-resistant bacteria, more research is being done on these antibiotics, leading to new and effective options. Their ability to treat serious infections makes them a key part of the market, benefiting both doctors and patients.
The market is divided into two categories based on Disease: Skin Infection, HABP/VABP, Blood Stream Infection, and Others. The skin infection segment is the most prominent. Skin infections are common and can be caused by a variety of bacteria, making effective treatments essential. Peptide antibiotics are frequently used because they effectively target these bacteria. Since skin infections are widespread and can lead to more serious complications if left untreated, there is a strong demand for these antibiotics. This focus on treating skin infections helps drive growth in the market and supports both healthcare providers and patients.
Peptide Antibiotics Market- Geographical Insights
The peptide antibiotics market in North America is growing rapidly. This rise is due to the increasing need for new antibiotics to fight drug-resistant bacteria. Many hospitals and healthcare providers are looking for effective treatments. Research and development in this area are getting more funding, which helps create new peptide antibiotics.
Moreover, awareness of the benefits of these treatments is spreading among doctors and patients. The market is also supported by regulatory frameworks that encourage innovation. Overall, North America is becoming a key player in the peptide antibiotics industry.
The peptide antibiotics market is highly competitive, with key players like Baxter International, Novartis, and Merck leading the way. These companies focus on developing new and effective antibiotics to tackle rising resistance. Others, like AstraZeneca and Boehringer Ingelheim, also invest in research to innovate and improve their product offerings. Sandoz and Hikma Pharmaceuticals specialize in generics, making treatments more accessible. Meanwhile, Amgen and Gilead Sciences focus on unique therapies to meet specific medical needs. Overall, these companies are striving to enhance their positions through collaboration, research, and expanding their product lines to address global health challenges.
In September 2024, Agilent Technologies Inc. finalized its acquisition of BIOVECTRA, a Canadian contract development and manufacturing organization (CDMO) that focuses on biologics, highly potent active pharmaceutical ingredients, and other compounds for targeted therapies.
In August 2024, Bora Pharmaceuticals Co., Ltd. strategically invested in Tanvex Biopharma Co., Ltd. As part of this partnership, Bora Biologics, a subsidiary of Bora that specializes in large molecule CDMO, will merge its biomanufacturing facilities with Tanvex to establish a global service for the development and supply of biologics.